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Neolignans are a class of natural products with a wide range of biological effects. These 
substances are of great synthetic and biological interest, especially in searching for novel anticancer 
agents. In this paper, we report the synthesis of a new subclass of 8,4’-oxyneolignan analogues 
(β-ketoethers and β-ketoesters) and their cell viability assay on twenty four different cancer cells, 
among leukemias and carcinomas. Three compounds inhibited the growth of most human cancer 
cells. 2-Oxo-2-phenylethyl(2E)-3-[4-(2-oxo-2-phenylethoxy) phenyl]prop-2-enoate showed an 
antiproliferative activity superior to doxorubicin for U-87, U-138 MG and H1299 cell types and 
(E)-2-oxo-2-phenylethyl 3-(3-methoxy-4-(2-oxo-2-phenylethoxy)phenyl)acrylate was found to 
be very selective, demonstrating a growth inhibition of 92.0% against KG-1 cells. Furthermore, 
1-oxo-1-phenylpropan-2-yl cinnamate exhibited significant inhibition activity in a range of 52.2 to 
91.2% against twelve kinds of leukemia cell lines, revealing excellent results and very comparable 
to the reference drug.
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Introduction
Cancer is a generic term for a large group of diseases 
that can affect any part of the body and remains a leading 
cause of death worldwide. It is considered a public health 
problem according to the World Health Organization, and 
many efforts have been made towards its prevention and 
cure. Treatment usually involves a series of interventions, 
and approximately 90% of tumors can be treated with 
antiblastic drugs,1,2 which makes chemotherapy the most 
used treatment. However, these drugs are non-selective 
and are toxic to healthy tissues, especially those of rapid 
cell proliferation.2-5 As a consequence, there is an urgent 
need for novel and effective drugs that act against cancer.
Several substances have been thoroughly studied for 
their biological activities and a very promising class are the 
neolignans, which are substances derived from the oxidative 
coupling of allyl and/or propenyl phenols and are normally 
found in plants of the Myristicacea family.6-8 Neolignans 
have a wide range of biological effects such as antioxidant,9-14 
antibacterial,15-17 anti-inflammatory,12,18-21 antifungal,22,23 
anti-leishmanial,24-28 anti-trypanosomastid,27,28 and 
anticancer activity,13,14,29,30 among others.31-34 Therefore, this 
type of natural product is of great synthetic and biological 
interest, especially in searching for novel anticancer 
agents. In this paper, we report the synthesis of new 
8,4’-oxyneolignan analogues and the cell viability assays 
for different neoplasms, among leukemias and carcinomas.
Experimental
Chemistry
All reagents were purchased from commercial suppliers 
and were used as received, unless otherwise specified. 
Reactions were monitored by thin layer chromatography 
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(TLC) using aluminum plates from Merck (silica gel 
60 F254). Melting points (mp) were determined using a 
PFM II apparatus (model 382). Proton (1H) and carbon 
(13C) nuclear magnetic resonance (NMR) spectra were 
recorded on the following spectrometers: Bruker AC 250/P, 
Varian Mercury Plus 300 MHz, Bruker Avance 600 MHz or 
Varian Inova 500 MHz. Chemical shifts are reported in ppm 
(d) with values relative to TMS used as internal standard. 
High-resolution mass spectra (HRMS) were recorded 
on a VG AutoSpec High Resolution Mass Spectrometer 
(Micromass Company) or on a triple TOF 5600+ High 
Resolution Mass Spectrometer (AB Sciex) with internal 
calibration and direct solution (1 ppm in methanol).
General procedure for the synthesis of 8,4’-oxyneolignan 
analogues: β-ketoesters and β-ketoethers
A solution of 1.02 equivalent of phenols (or 
0.51 equivalent of cinnamic acid derivatives) and 
1.80 equivalent of anhydrous K2CO3 in anhydrous butanone 
(4.5 mL of solvent per mmol of phenol or cinnamic acid 
derivative) was stirred for 15 min at room temperature. After 
this period, a solution of 1.00 equivalent of α-bromoketone 
in anhydrous butanone (1.5 mL of solvent per mmol 
of ketone) was added dropwise and the mixture was 
stirred under reflux for 24 h. The solution was cooled 
to room temperature, filtered, and the residue washed 
with CHCl3. The solution was concentrated in vacuum 
(to remove butanone), diluted with H2O, and extracted 
with CHCl3 (3×). The organic extracts were combined, 
washed with water, 5% NaOH solution, brine, dried over 
Na2SO4 and then filtered and concentrated in vacuum. The 
reaction products were purified by crystallization or column 
chromatography.
2-(4-Nitro-phenoxy)-1-phenyl-ethanone (3a)
Obtained according to the general procedure from 
1.50 g (10.76 mmol) of 4-nitrophenol, 2.10 g (10.55 mmol) 
of phenacyl bromide, 2.62 g (19.00 mmol) of K2CO3 and 
purified by recrystallization from acetone/hexane (84% 
yield). The product obtained was an orange crystalline solid 
(mp 148-150 °C). 1H NMR (600 MHz, CDCl3) d 8.20 (d, 
J 9.0 Hz, 2H, Ar-H), 7.99 (d, J 7.2 Hz, 2H, Ar-H), 7.66 (t, 
J 7.2 Hz, 1H, Ar-H), 7.54 (t, J 9.0 Hz, 2H, Ar-H), 6.99 (d, 
J 9.0 Hz, 2H, Ar-H), 5.43 (s, 2H, CH2); 13C NMR (150 MHz, 
CDCl3) d 192.8, 163.0, 142.1, 134.4, 134.0, 129.1, 128.0, 
125.9, 114.8, 70.6. HREIMS m/z 280.0581 [M + Na]+ 
(calcd. for C14H11NNaO4+, 280.0580).
2-(3,5-Dichlorophenoxy)-1-phenylethanone (3b)
Obtained according to the general procedure from 0.83 g 
(5.07 mmol) of 2,4-dichlorophenol, 1.00 g (5.02 mmol) of 
phenacyl bromide and 1.25 g (9.04 mmol) of K2CO3 and 
purified by recrystallization from acetone/hexane (42% 
yield). The product obtained was a light brown crystalline 
solid (mp 74-75 °C). 1H NMR (600 MHz, CDCl3) d 8.00 
(d, J 7.2 Hz, 2H, Ar-H), 7.63 (t, J 7.2 Hz, 1H, Ar-H), 7.50 
(t, J 7.2 Hz, 2H, Ar-H), 7.38 (d, J 3.0 Hz, 1H), 7.13 (dd, J1 
9.0 Hz, J2 3.0 Hz, 1H, Ar-H), 6.78 (d, J 9.0 Hz, 1H, Ar-H), 
5.34 (s, 2H, CH2); 13C NMR (150 MHz, CDCl3) d 193.7, 
152.7, 134.3, 134.3, 130.4, 129.0, 128.3, 127.7, 127.0, 
124.3, 115.1, 72.1. HREIMS m/z 302.9949 [M + Na]+ 
(calcd. for C14H10Cl2NaO2+, 302.9951).
2-(4-Nitro-phenoxy)-1-phenyl-propan-1-one (3c)
Obtained according to the general procedure from 
0.55 g (3.93 mmol) of 4-nitrophenol, 0.82 g (3.85 mmol) 
of 2-bromopropiophenone and 0.96 g (6.93 mmol) of 
K2CO3 and purified by recrystallization from methanol 
(91% yield). The product obtained was a white crystalline 
solid (mp 78-80 °C). 1H NMR (600 MHz, CDCl3) d 8.14 (d, 
J 9.0 Hz, 2H, Ar-H), 8.04 (d, J 7.8 Hz, 2H, Ar-H), 7.63 (t, 
J 7.8 Hz, 1H, Ar-H), 7.51 (t, J 7.8 Hz, 2H, Ar-H), 6.90 (d, 
J 9.0 Hz, 2H, Ar-H), 5.63 (q, J 6.6 Hz, 1H, CH), 1.78 (d, 
J 6.6 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 197.2, 
162.4, 142.0, 134.2, 133.7, 129.0, 128.7, 126.0, 115.0, 
76.9, 18.8. HREIMS m/z 294.0737 [M + Na]+ (calcd. for 
C15H13NNaO4+, 294.0737).
2-Pentachlorophenyloxy-1-phenyl-ethanone (3d)
Obtained according to the general procedure from 0.68 g 
(2.56 mmol) of pentachlorophenol, 0.50 g (2.51 mmol) of 
phenacyl bromide and 0.62 g (4.52 mmol) of K2CO3 and 
purified by recrystallization from methanol/CH2Cl2 (100% 
yield). The product obtained was a white crystalline solid 
(mp 125-127 °C). 1H NMR (600 MHz, CDCl3) d 7.97 (d, 
J 7.2 Hz, 2H, Ar-H), 7.63 (t, J 7.2 Hz, 1H, Ar-H), 7.51 (t, 
J 7.2 Hz, 2H, Ar-H), 5.30 (s, 2H, CH2); 13C NMR (150 MHz, 
CDCl3) d 192.1, 151.2, 134.3, 134.2, 132.2, 130.2, 129.1, 
128.3, 128.2, 74.8. HREIMS m/z 406.8745 [M + Na]+ 
(calcd. for C14H7Cl5NaO2+, 406.8752).
1-Phenyl-2-m-tolyloxy-ethanone (3e)
Obtained according to the general procedure from 0.28 g 
(2.56 mmol) of m-cresol, 0.50 g (2.51 mmol) of phenacyl 
bromide and 0.62 g (4.52 mmol) of K2CO3 and purified by 
recrystallization from methanol (69% yield). The product 
obtained was a yellow crystalline solid (mp 70-72 °C). 
1H NMR (600 MHz, CDCl3) d 8.01 (d, J 7.8 Hz, 2H, Ar-H), 
7.61 (t, J 7.8 Hz, 1H, Ar-H), 7.50 (t, J 7.8 Hz, 2H, Ar-H), 7.16 
(t, J 7.8 Hz, 1H, Ar-H), 6.80 (d, J 7.8 Hz, 1H, Ar-H), 6.78 (s, 
1H, Ar-H), 6.74 (dd, J1 7.8 Hz, J2 1.8 Hz, 1H, Ar-H), 5.24 (s, 
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2H, CH2), 2.32 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 
194.7, 158.1, 139.7, 134.7, 133.8, 129.3, 128.8, 128.2, 122.5, 
115.7, 111.6, 70.8, 21.5. HREIMS m/z 249.0891 [M + Na]+ 
(calcd. for C15H14NaO2+, 249.0886).
2-(3,5-Dichlorophenoxy)-1-phenylpropan-1-one (3f)
Obtained according to the general procedure from 0.39 g 
(2.40 mmol) of 2,4-dichlorophenol, 0.50 g (2.35 mmol) of 
2-bromopropiophenone and 0.58 g (4.23 mmol) of K2CO3 
and purified by column chromatography in hexane/
acetate (80:20) (54% yield). The product was obtained 
as a colorless oil. 1H NMR (600 MHz, CDCl3) d 8.08 (d, 
J 7.2 Hz, 2H, Ar-H), 7.59 (t, J 7.2 Hz, 1H, Ar-H), 7.47 (t, 
J 7.2 Hz, 2H, Ar-H), 7.35 (d, J 2.6 Hz, 1H, Ar-H), 7.06 
(dd, J1 8.8 Hz, J2 2.6 Hz, 1H, Ar-H), 6.72 (d, J 8.8 Hz, 1H, 
Ar-H), 5.40 (q, J 6.8 Hz, 1H, CH), 1.78 (d, J 8.8 Hz, 3H, 
CH3); 13C NMR (150 MHz, CDCl3) d 194.7, 158.1, 139.7, 
134.7, 133.8, 129.3, 128.8, 128.2, 122.5, 115.7, 111.61, 
70.8, 21.5. HREIMS m/z 317.0115 [M + Na]+ (calcd. for 
C15H12Cl2NaO2+, 317.0107).
2-Pentachlorophenyloxy-1-phenyl-propan-1-one (3g)
Obtained according to the general procedure from 0.64 g 
(2.40 mmol) of pentachlorophenol, 0.50 g (2.35 mmol) of 
2-bromopropiophenone and 0.58 g (4.23 mmol) of K2CO3 
and purified by recrystallization from methanol (66% 
yield). The product obtained was a light brown crystalline 
solid (mp 111-112 °C). 1H NMR (600 MHz, CDCl3) d 8.04 
(d, J 7.2 Hz, 2H, Ar-H), 7.61 (t, J 7.2 Hz, 1H, Ar-H), 7.50 
(t, J 7.2 Hz, 2H, Ar-H), 5.70 (q, J 7.0 Hz, 1H, CH), 1.68 (d, 
J 7.0 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 196.3, 
150.7, 134.5, 133.9, 132.2, 129.7, 129.1, 128.9, 128.4, 
82.1, 18.8. HREIMS m/z 420.8903 [M + Na]+ (calcd. for 
C15H9Cl5NaO2+, 420.8908).
1-Phenyl-2-m-tolyloxy-propan-1-one (3h)
Obtained according to the general procedure from 
0.26 g (2.40 mmol) of m-cresol, 0.50 g (2.35 mmol) of 
2-bromopropiophenone and 0.58 g (4.23 mmol) of K2CO3 
and purified by recrystallization from methanol (54% yield). 
The product obtained was a light brown crystalline solid (mp 
109-111 °C). 1H NMR (600 MHz, CDCl3) d 8.07 (d, J 7.8 Hz, 
2H, Ar-H), 7.57 (t, J 7.8 Hz, 2H, Ar-H), 7.46 (t, J 7.8 Hz, 2H, 
Ar-H), 7.10 (t, J 7.9 Hz, 1H, Ar-H), 6.75 (d, J 7.9 Hz, 1H, 
Ar-H), 7.10 (t, J 7.9 Hz, 1H, Ar-H), 6.75 (d, J 7.9 Hz, 1H, 
Ar-H), 6.72 (s,1H, Ar-H), 6.65 (dd, J1 7.9 Hz, J2 2.4 Hz, 1H, 
Ar-H), 5.45 (q, J 7.0 Hz, 1H, CH), 2.27 (s, 3H, CH3), 1.69 (d, 
J 7.0 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 199.2, 
157.6, 139.8, 134.4, 133.7, 129.4, 129.0, 128.9, 122.5, 116.3, 
112.0, 76.7, 21.6, 18.8. HREIMS m/z 263.1051 [M + Na]+ 
(calcd. for C16H16NaO2+, 263.1043).
1-(4-Bromophenyl)-2-(3,5-dichlorophenoxy)ethanone (3i)
Obtained according to the general procedure from 0.30 g 
(1.84 mmol) of 2,4-dichlorophenol, 0.50 g (1.80 mmol) of 
2,4’-dibromoacetophenone and 0.45 g (3.24 mmol) of 
K2CO3 and purified by recrystallization from methanol/
CH2Cl2 (39% yield). The product obtained was a white 
crystalline solid (mp 99-101 °C). 1H NMR (600 MHz, 
CDCl3) d 7.88 (d, J 8.4 Hz, 2H, Ar-H), 7.65 (d, J 9.0 Hz, 
2H, Ar-H), 7.39 (d, J 2.4 Hz, 1H, Ar-H), 7.14 (dd, J1 9.0 Hz, 
J2 2.4 Hz, 1H, Ar-H), 6.78 (d, J 9.0 Hz, 1H, Ar-H), 5.25 
(s, 2H, CH2); 13C NMR (150 MHz, CDCl3) d 193.1, 152.4, 
132.9, 132.2, 130.4, 129.8, 129.5, 127.6, 127.2, 124.2, 
114.9, 72.1. HREIMS m/z 380.9042 [M + Na]+ (calcd. for 
C14H9BrCl2NaO2+, 380.9056).
1-(4-Bromophenyl)-2-(m-tolyloxy)ethanone (3j)
Obtained according to the general procedure from 
0.10 g (0.92 mmol) of m-cresol, 0.25 g (0.90 mmol) of 
2,4’-dibromoacetophenone and 0.23 g (1.62 mmol) of 
K2CO3 and purified by recrystallization from methanol 
(69% yield). The product obtained was a light brown 
crystalline solid (mp 91-93 °C). 1H NMR (600 MHz, CDCl3) 
d 7.88 (d, J 8.4 Hz, 2H, Ar-H), 7.63 (d, J 8.4 Hz, 2H, Ar-H), 
7.16 (t, J 8.0 Hz, 1H, Ar-H), 6.81 (d, J 8.0 Hz, 1H, Ar-H), 
6.76 (s, 1H, Ar-H), 6.72 (d, J 8.0 Hz, 1H, Ar-H), 5.17 (s, 
2H, CH2), 2.32 (s, 3H, CH3); 13C NMR (150 MHz, CDCl3) 
d 194.1, 157.9, 139.8, 133.4, 132.1, 129.8, 129.3, 129.1, 
122.7, 115.6, 111.5, 70.9, 21.5. HREIMS m/z 326.9997 
[M + Na]+ (calcd. for C15H13BrNaO2+, 326.9992).
2-Oxo-2-phenylethyl(2E)-3-[4-(2-oxo-2-phenylethoxy) 
phenyl]prop-2-enoate (4a)
Obtained according to the general procedure from 
0.21 g (1.28 mmol) of p-hydroxycinnamic acid, 0.50 g 
(2.51 mmol) of phenacyl bromide and 0.62 g (4.52 mmol) of 
K2CO3 and purified by recrystallization from acetone (55% 
yield). The product obtained was a colorless crystalline 
solid (mp 145-147 °C). 1H NMR (250 MHz, DMSO-d6) 
d 8.03 (d, J 8.8 Hz, 2H, Ar-H), 8.00 (d, J 8.8 Hz, 2H, 
Ar-H), 7.70 (t, J 8.8 Hz, 4H, Ar-H; d, J 15.8 Hz, 1H, CH), 
7.50-7.63 (m, 4H, Ar-H), 7.04 (d, J 8.5 Hz, 2H, Ar-H), 6.65 
(d, J 15.8 Hz, 1H, CH), 5.68 (s, 2H, CH2), 5.60 (s, 2H, CH2); 
13C NMR (62.5 MHz, DMSO-d6) d 194.2, 193.0, 165.9, 
160.0, 145.1, 134.3, 134.0, 133.9, 130.2, 128.9, 128.9, 
127.9, 127.8, 126.9, 115.1, 114.8, 70.2, 66.4. HREIMS 
m/z 401.1389 [M + H]+ (calcd. for C25H21O5+, 401.1384).
(E)-2-Oxo-2-phenylethyl 3-(3-methoxy-4-(2-oxo-2-phenyl-
ethoxy)phenyl)acrylate (4b)
Obtained according to the general procedure from 
0.25 g (1.28 mmol) of ferulic acid, 0.50 g (2.51 mmol) of 
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phenacyl bromide and 0.57 g (4.52 mmol) of K2CO3 and 
purified by recrystallization from methanol (74% yield). 
The product obtained was a white solid (mp 135-137 °C). 
1H NMR (600 MHz, CDCl3) d 8.01 (d, J 7.3 Hz, 2H, Ar-H), 
7.96 (d, J 7.3 Hz, 2H, Ar-H), 7.73 (d, J 16.1 Hz, 1H, CH), 
7.62 (td, J1 7.3 Hz, J2 3.6 Hz, 2H, Ar-H), 7.50 (td, J1 7.8 Hz, 
J2 2 Hz, 4H, Ar-H), 7.12 (d, J 1.8 Hz, 1H, Ar-H), 7.06 (dd, 
J1 8.4 Hz, J2 1.8 Hz, 1H, Ar-H), 6.80 (d, J 8.4 Hz, 1H, Ar-H), 
6.48 (d, J 16.1 Hz, 1H, CH), 5.47 (s, 2H, CH2), 5.40 (s, 2H, 
CH2), 3.93 (s, 3H, OCH3); 13C NMR (150 MHz, CDCl3) 
d 193.8, 192.4, 166.4, 149.8, 149.7, 145.8, 134.4, 134.4, 
134.0, 133.9, 128.9, 128.6, 128.1, 127.8, 122.5, 115.3, 
113.9, 110.8, 71.6, 66.0, 56.0. HREIMS m/z 453.1307 
[M + Na]+ (calcd. for C26H22NaO6+, 453.1309).
( E ) - 1 - ( 4 - M e t h o x y p h e n y l ) - 1 - o x o p r o p a n - 2 - y l 
3-(4-((1-(4-methoxyphenyl)-1-oxopropan-2-yl)oxy)phenyl)
acrylate (4c)
Obtained according to the general procedure from 
0.10 g (0.53 mmol) of p-hydroxycinnamic acid, 0.25 g 
(1.03 mmol) of 4-methoxy-8-bromopropiophenone 
and 0.26 g (1.85 mmol) of K2CO3 and purified by 
recrystallization from methanol (71% yield). The product 
obtained was a colorless crystalline solid (mp 142-144 °C). 
1H NMR (400 MHz, DMSO-d6) d 8.12 (d, J 8.8 Hz, 2H, 
Ar-H), 8.05 (d, J 8.8 Hz, 2H, Ar-H), 7.70 (d, J 8.8 Hz, 2H, 
Ar-H), 7.64 (d, J 16.0 Hz, 1H, CH), 7.19-7.08 (m, 4H, 
Ar-H), 6.94 (d, J 8.8 Hz, 2H, Ar-H), 6.61 (d, J 16.0 Hz, 1H, 
CH), 6.16-6.06 (m, 2H, CH), 3.91 (s, 3H, OCH3), 3.90 (s, 
3H, OCH3), 1.59 (d, J 7.0 Hz, 3H, CH3), 1.52 (d, J 7.0 Hz, 
3H, CH 3); 13C NMR (100 MHz, DMSO-d6) d 196.1, 195.1, 
165.8, 163.8, 163.6, 159.2, 144.9, 130.9, 130.8, 130.3, 
126.9, 126.7, 126.7, 115.3, 115.0, 114.3, 114.2, 74.3, 71.2, 
55.7, 18.5, 17.2. HREIMS m/z 489.1941 [M + H]+ (calcd. 
for C29H29O7+, 489.1942).
3-[3-(2-Oxo-2-phenyl-ethoxy)-phenyl]-acrylic acid (5a)
Obtained according to the general procedure from 
0.42 g (2.56 mmol) 3-hydroxycinnamic acid, 1.00 g 
(5.02 mmol) of phenacyl bromide and 1.24 g (9.00 mmol) 
of K2CO3 and purified by recrystallization from methanol 
(76% yield). The product obtained was a white crystalline 
solid (mp 139-141 °C). 1H NMR (600 MHz, CDCl3) d 8.02 
(d, J 7.3 Hz, 2H, Ar-H), 7.96 (d, J 7.3 Hz, 2H, Ar-H), 7.76 
(d, J 16.0 Hz, 1H, CH), 7.59-7.68 (m, 2H, Ar-H), 7.48-7.56 
(m, 4H, Ar-H), 7.32 (t, J 8.0 Hz, 1H, Ar-H), 7.19 (d, 
J 8.0 Hz, 1H, Ar-H), 7.12 (s, 1H, Ar-H), 7.00 (dd, J1 8.0 Hz, 
J2 2.2 Hz, 1H, Ar-H), 6.57 (d, J 16.0 Hz, 1H, CH), 5.47 (s, 
2H, CH2), 5.32 (s, 2H, CH2); 13C NMR (150 MHz, CDCl3) 
d 194.1, 192.4, 166.3, 158.5, 145.9, 135.9, 134.6, 134.4, 
134.1, 134.0, 130.2, 129.0, 129.0, 128.2, 128.0, 122.0, 
117.7, 117.3, 114.2, 70.9, 66.3. HREIMS m/z 423.1208 
[M + Na]+ (calcd. for C25H20NaO5+, 423.1203).
(E)-2-(4-Nitrophenyl)-2-oxoethyl 3-(3-(2-(4-nitrophenyl)-
2-oxoethoxy)phenyl)acrylate (5b)
Obtained according to the general procedure from 
0.09 g (0.52 mmol) of 3-hydroxycinnamic acid, 0.25 g 
(1.02 mmol) of p-nitrophenacyl bromide and 0.25 g 
(1.84 mmol) of K2CO3 and purified by recrystallization 
from methanol (45% yield). The product obtained was a 
light brown crystalline solid (mp 101-103 °C). 1H NMR 
(600 MHz, CDCl3) d 8.20-8.14 (m, 2H, Ar-H), 7.80-7.73 
(m, 2H, Ar-H), 7.71-7.62 (m, 2H), 7.56-7.46 (m, 3H, Ar-H), 
7.26 (t, J 7.8 Hz, 1H, Ar-H), 7.09 (d, J 7.7 Hz, 1H, Ar-H), 
6.85 (s, 1H, Ar-H), 6.82 (d, J 8.4 Hz, 1H, Ar-H), 6.28 (d, 
J 16.1 Hz, 1H, CH), 5.12 (s, 2H, CH2), 4.91 (s, 2H, CH2); 
13C NMR (150 MHz, CDCl3) d 198.9, 197.4, 165.6, 157.5, 
147.3, 146.3, 145.8, 135.5, 134.7, 134.4, 134.4, 134.2, 
131.5, 131.4, 130.1, 128.8, 128.8, 124.0, 123.8, 122.2, 
117.0, 116.8, 114.1, 72.0, 67.6. HREIMS m/z 513.0901 
[M + Na]+ (calcd. for C25H18N2NaO9+, 513.0905).
2-Oxo-2-phenylethyl cinnamate (6a)
Obtained according to the general procedure from 
0.38 g (2.56 mmol) of cinnamic acid, 0.50 g (2.51 mmol) 
of phenacyl bromide and 0.62 g (4.52 mmol) of K2CO3 
and purified by recrystallization from acetone (86% yield). 
The product obtained was a colorless crystalline solid 
(mp 141-143 °C). 1H NMR (600 MHz, CDCl3) d 7.96 (d, 
J 7.2 Hz, 2H, Ar-H), 7.81 (d, J 16.1 Hz, 1H, CH), 7.62 (t, 
J 7.2 Hz, 1H, Ar-H), 7.55 (s, 2H, Ar-H), 7.50 (t, J 7.2 Hz, 
2H, Ar-H), 7.40 (s, 3H, Ar-H), 6.60 (d, J 16.1 Hz, 1H, 
CH), 5.80 (s, 2H, CH2); 13C NMR (150 MHz, CDCl3) 
d 192.4, 166.4, 146.3, 134.5, 134.4, 134.0, 130.7, 129.1, 
129.0, 128.4, 128.0, 117.2, 66.3. HREIMS m/z 289.0836 
[M + Na]+ (calcd. for C17H14NaO3+, 289.0836).
2-(4-Nitrophenyl)-2-oxoethyl cinnamate (6b)
Obtained according to the general procedure from 
0.38 g (2.59 mmol) of cinnamic acid, 0.62 g (2.54 mmol) of 
4-nitrophenacyl bromide and 0.63 g (4.56 mmol) of K2CO3 
and purified by recrystallization from acetone/hexane (75% 
yield). The product obtained was a light yellow crystalline 
solid (mp 157-158 °C). 1H NMR (600 MHz, CDCl3) d 8.36 
(d, J 8.8 Hz, 2H, Ar-H), 8.12 (d, J 8.8 Hz, 2H, Ar-H), 7.81 
(d, J 16.0 Hz, 1H, CH), 7.52-7.63 (m, 2H, Ar-H), 7.36-7.45 
(m, 3H, Ar-H), 6.58 (d, J 16.0 Hz, 1H, CH), 5.46 (s, 2H, 
CH2); 13C NMR (150 MHz, CDCl3) d 191.3, 166.1, 150.7, 
146.7, 138.8, 134.1, 130.7, 129.0, 129.0, 128.3, 127.9, 
124.1, 116.4, 66.2. HREIMS m/z 334.0696 [M + Na]+ 
(calcd. for C17H13NNaO5+, 334.0686).
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1-Oxo-1-phenylpropan-2-yl cinnamate (6c)
Obtained according to the general procedure from 
0.36 g (2.40 mmol) of cinnamic acid, 0.50 g (2.35 mmol) 
of 2-bromopropiophenone and 0.58 g (4.23 mmol) of 
K2CO3 and purified by recrystallization from methanol 
(57% yield). The product obtained was a white crystalline 
solid (mp 70-71 °C). 1H NMR (600 MHz, CDCl3) d 7.99 
(d, J 7.2 Hz, 2H, Ar-H), 7.74 (d, J 16.2 Hz, 1H, CH), 7.59 
(t, J 7.2 Hz, 1H, Ar-H), 7.51-7.55 (m, 2H, Ar-H), 7.49 (t, 
J 7.2 Hz, 2H, Ar-H), 7.37-7.40 (m, 3H, Ar-H), 6.54 (d, 
J 16.2 Hz, 1H, CH), 6.12 (q, J 7.0 Hz, 1H, CH), 1.61 (d, 
J 7.0 Hz, 3H, CH3); 13C NMR (150 MHz, CDCl3) d 196.9, 
166.2, 145.9, 134.5, 134.3, 133.5, 130.5, 128.9, 128.8, 
128.5, 128.2, 117.2, 71.4, 17.2. HREIMS m/z 303.0996 
[M + Na]+ (calcd. for C18H16NaO3+, 303.0992).
2-(4-Chlorophenyl)-2-oxoethyl cinnamate (6d)
Obtained according to the general procedure from 
0.34 g (2.32 mmol) of cinnamic acid, 0.53 g (2.27 mmol) of 
2-bromo-4’-chloroacetophenone and 0.57 g (4.10 mmol) of 
K2CO3 and purified by recrystallization from acetone (59% 
yield). The product obtained was a white crystalline solid 
(mp 128-130 °C). 1H NMR (400 MHz, CDCl3) d 7.89 (d, 
J 8.6 Hz, 2H, Ar-H), 7.80 (d, J 16.0 Hz, 1H, CH), 7.52-7.56 
(m, 2H, Ar-H), 7.46 (d, J 8.6 Hz, 2H, Ar-H), 7.38-7.41 
(m, 3H, Ar-H), 6.58 (d, J 16.0 Hz, 1H, CH), 5.42 (s, 2H, 
CH2); 13C NMR (100 MHz, CDCl3) d 191.2, 166.1, 146.2, 
140.3, 134.1, 132.5, 130.5, 129.2, 128.9, 128.5, 128.2, 




Obtained according to the general procedure from 0.49 g 
(2.56 mmol) of 3,4-(methylenedioxy)cinnamic acid, 0.50 g 
(2.51 mmol) of phenacyl bromide and 0.59 g (4.52 mmol) of 
K2CO3 and purified by recrystallization from acetone/hexane 
(69% yield). The product obtained was a colorless crystalline 
solid (mp 144-146 °C). 1H NMR (250 MHz, CDCl3) d 
7.95 (d, J 7.4 Hz, 2H, Ar-H), 7.71 (d, J 16.0 Hz, 1H, CH), 
7.61 (t, J 7.4 Hz, 1H, Ar-H), 7.49 (t, J 7.4 Hz, 2H, Ar-H), 
7.06-7.02 (m, 2H, Ar-H), 6.81 (d, J 7.9 Hz, 1H, Ar-H), 6.42 
(d, J 16.0 Hz, 1H, CH), 6.01 (s, 2H, OCH2O), 5.46 (s, 2H, 
CH2); 13C NMR (62.5 MHz, CDCl3) d 192.4, 166.4, 149.8, 
148.3, 145.8, 134.3, 133.8, 129.2, 128.8, 127.8, 124.7, 114.8, 
108.5, 106.6, 101.6, 66.0. HREIMS m/z 349.0478 [M + K]+ 
(calcd. for C18H14KO5+, 349.0473).
(E)-2-(4-Chlorophenyl)-2-oxoethyl-3-(3,4,5 trimethoxy-
phenyl)acrylate (6f)
Obtained according to the general procedure from 
1.04 g (4.37 mmol) of 3,4,5-trimethoxycinnamic acid, 
1.00 g (4.28 mmol) of 2-bromo-4’-chloroacetophenone 
and 1.09 g (7.70 mmol) of K2CO3 and purified by 
recrystallization from acetone (45% yield). The product 
obtained was a white crystalline solid (mp 117-119 °C). 
1H NMR (400 MHz, CDCl3) d 7.90 (d, J 8.0 Hz, 2H, Ar-H), 
7.71 (d, J 16.0 Hz, 1H, CH), 7.48-7.46 (m, 2H, Ar-H), 
6.78 (s, 2H, Ar-H), 6.50 (d, J 16.0 Hz, 1H, CH), 5.44 
(s, 2H, CH2), 3.89 (s, 9H, OCH3); 13C NMR (100 MHz, 
CDCl3) d 191.2, 166.1, 153.3, 146.2, 140.3, 140.3, 132.5, 
129.6, 129.1, 115.9, 105.4, 65.8, 60.9, 56.1. HREIMS 
m/z 391.0948 [M + H]+ (calcd. for C20H20ClO6+, 391.0943).
(E)-Methyl-3-(3-methoxy-4-(2-oxo-2-phenylethoxy) phenyl)
acrylate (7a)
Obtained according to the general procedure from 
0.75 g (3.59 mmol) of methyl ferulate, 0.70 g (3.52 mmol) 
of phenacyl bromide and 0.88 g (6.34 mmol) of K2CO3 
and purified by recrystallization from ethanol (53% yield). 
The product obtained was a colorless crystalline solid 
(mp 105-107 °C). 1H NMR (500 MHz, CDCl3) d 8.00 (d, 
J 8.0 Hz, 2H, Ar-H), 7.63-7.59 (m, 2H, Ar-H/CH), 7.50 (t, 
J 8.0 Hz, 2H, Ar-H), 7.07 (s, 1H, Ar-H), 7.02 (d, J 8.0 Hz, 
1H, Ar-H), 6.77 (d, J 8.0 Hz, 1H, Ar-H), 6.31 (d, J 16.0 Hz, 
1H, CH), 5.41 (s, 2H, CH2), 3.92 (s, 3H, OCH3), 3.79 (s, 
3H, OCH3); 13C NMR (125 MHz, CDCl3) d 193.7, 167.5, 
149.5, 149.3, 144.5, 134.2, 133.9, 128.8, 128.5, 127.9, 
122.0, 115.9, 113.6, 110.4, 71.3, 55.9, 51.6. HREIMS 
m/z 327.1233 [M + H]+ (calcd. for C19H19O5+, 327.1227).
3-{4-[2-(4-Bromo-phenyl)-2-oxo-ethoxy]-3-methoxy-phenyl}-
acrylic acid methyl ester (7b)
Obtained according to the general procedure from 
0.19 g (0.92 mmol) of methyl ferulate, 0.25 g (0.90 mmol) 
of 2,4’-dibromoacetophenone and 0.22 g (1.62 mmol) of 
K2CO3 and purified by recrystallization from acetone/
CH2Cl2 (68% yield). The product obtained was a light 
yellow crystalline solid (mp 160-162 °C). 1H NMR 
(600 MHz, CDCl3) d 7.88 (d, J 8.4 Hz, 2H, Ar-H), 7.64 
(d, J 8.4 Hz, 2H, Ar-H), 7.61 (d, J 16.2 Hz, 1H, CH), 7.07 
(d, J 1.8 Hz, 1H, Ar-H), 7.03 (dd, J1 8.4 Hz, J2 1.8 Hz, 1H, 
Ar-H), 6.79 (d, J 8.4 Hz, 1H, Ar-H), 6.31 (d, J 16.2 Hz, 1H, 
CH), 5.31 (s, 2H, CH2), 3.91 (s, 3H, CH3), 3.79 (s, 3H, CH3); 
13C NMR (150 MHz, CDCl3) d 193.3, 167.5, 149.8, 149.2, 
144.4, 133.1, 132.2, 129.7, 129.2, 128.9, 122.0, 116.3, 
114.1, 110.7, 71.8, 56.0, 51.6. HREIMS m/z 427.0158 
[M + Na]+ (calcd. for C19H17BrNaO5+, 427.0152).
(E)-Methyl 3-(3-((1-oxo-1-phenylpropan-2-yl)oxy)phenyl)
acrylate (8)
Obtained according to the general procedure from 
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0.22 g (1.22 mmol) of methyl 3-(3-hydroxyphenyl)acrylate, 
0.25 g (1.20 mmol) of 2-bromopropiophenone and 0.30 g 
(2.16 mmol) of K2CO3 and purified by recrystallization 
from acetone/CH2Cl2 (88% yield). The product obtained 
was a light yellow crystalline solid (mp 115-117 °C). 
1H NMR (600 MHz, CDCl3) d 8.06 (d, J 7.2 Hz, 2H, Ar-H), 
7.63-7.53 (m, 1H, Ar-H/CH), 7.48 (t, J 7.2 Hz, 2H, Ar-H), 
7.24 (t, J 7.8 Hz, 1H, Ar-H), 7.10 (d, J 7.8 Hz, 1H, Ar-H), 
7.02 (s, 1H, Ar-H), 6.87 (dd, J1 7.8 Hz, J2 1.8 Hz, 1H, Ar-H), 
6.34 (d, J
 
15.6 Hz, 1H, CH), 5.50 (q, J 7.2 Hz, 1H, CH), 
3.79 (s, 3H, OCH3), 1.73 (d, J 7.2 Hz, 3H, CH3); 13C NMR 
(150 MHz, CDCl3) d 198.5, 167.2, 157.8, 144.4, 135.9, 
134.1, 133.8, 130.0, 128.8, 128.8, 121.3, 118.3, 116.9, 
114.7, 76.7, 51.7, 18.7. HREIMS m/z 333.1099 [M + Na]+ 
(calcd. for C19H18NaO4+, 333.1098).
2-Oxo-2-phenylethyl-4-(2-oxo-2-phenylethoxy)benzoate (9)
Obtained according to the general procedure from 
0.35 g (2.56 mmol) p-hydroxybenzoic acid, 0.50 g 
(2.51 mmol) of phenacyl bromide and 0.62 g (4.52 mmol) 
of K2CO3 and purified by recrystallization from ethanol 
(41% yield).
 
The product obtained was a white crystalline 
solid (mp 146-148 °C). 1H NMR (500 MHz, CDCl3) d 
8.07 (d, J 8.9 Hz, 2H, Ar-H), 7.98 (d, J 8.5 Hz, 2H, Ar-H), 
7.94 (d, J 8.5 Hz, 2H, Ar-H), 7.46-7.52 (m, 4H, Ar-H), 
6.97 (d, J 8.9 Hz, 2H, Ar-H), 5.54 (s, 2H, CH2), 5.37 
(s, 2H, CH2); 13C NMR (100 MHz, DMSO-d6) d 193.6, 
192.3, 165.5, 162.0, 134.4, 134.3, 134.1, 133.8, 132.1, 
128.9, 128.9, 128.1, 127.8, 122.7, 114.5, 70.5, 66.3. 
HREIMS m/z 397.1052 [M + Na]+ (calcd. for C23H18NaO5+, 
397.1047).
Biology
Cell culture and treatment
Human myeloid leukemia (KG-1, K-562, HL-60, NB4), 
human burkit lymphoma (RAMOS, RAJI), human lymphoid 
T leukemia (JURKAT, CEM, MOLT-4), human lymphoid B 
leukemia (NALM-6, SUP-B15, RS4;11), human prostatic 
adenocarcinoma (PC3, LNCaP), human ovarian carcinoma 
(NCI/ADR), human malignant neoplasm cervix uteri 
(HeLa), human breast adenocarcinoma (MCF-7), human 
osteosarcoma (HOS, U-2 0S, MG-63), human glioblastoma-
astrocytoma, epithelial-like (U-87 MG), human glioblastoma 
cell lines (U-138 MG) and human non-small cell lung 
cancer (NCI-H1299) were cultured in RPMI medium 
supplemented with 10% fetal calf serum (Gibco 16000-044), 
1% penicillin (10,000 IU mL-1) and streptomycin 10 mg mL-1 
(15,070 Gibco) and exposed to concentration of drugs 
(10 μM) in DMSO (0.1%) and maintained at 37 °C in 95% 
humidified atmosphere, containing 5% CO2.
In vitro cell viability assay - MTT assay
All steps in this assay were automated in Liquid 
Handling Workstation epMotion® 5070 (Eppendorf, 
Vaudaux, Schonenbuch, Switzerland). Cells were 
distributed in 96 wells (100 μL cells well-1) and incubated 
for 48 h, before addition of test compounds. Cells were 
then exposed to the compounds at a concentration of 
10 μM. After 24 h of exposure at 37 °C, cell viability was 
determined by colorimetric MTT35 (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazoliumbromide) based on the 
metabolic ability of active cells to convert the yellow 
MTT reagent into a blue insoluble salt (formazan), which 
is spectrophotometrically measured. Then, the amount of 
formazan produced was dissolved in solution containing 
150 μL of isopropanol and optical density was read by a 
spectrophotometer at 570 nm (Bio-Tek Power Wave XS). 
Absorbance of wells containing the compounds and those 
with cells in control (cells treated with vehicle, 0.1% 
DMSO) were compared to estimate the cell viability. The 
results were expressed as inhibition percentage relative to 
control (considered as 100%) and doxorubicin was used 
as a reference drug. Compound 6c was also evaluated for 
cytotoxicity against human leukemia cells, using the MTT 
method. Doxorubicin was used as positive control. All 
assays were performed in triplicate and mean ± standard 
deviation (SD) values were used to estimate cell viability.
Results and Discussion
Chemistry
In this work, 25 oxyneolignan analogues (β-ketoethers 
or β-ketoesters) were synthesized and the synthetic 
strategies for their preparation are summarized in 
Scheme 1. The β-ketoethers and β-ketoesters analogues 
3a-3j, 4a-4c, 5a-5b, 6a-6f, 7a-7b, 8 and 9 (Table 1) were 
obtained following a procedure described by Barata et al.26
Initially, the α-bromoketone intermediates 2a-2b 
were prepared according to a known procedure,26 then, 
without any purification due to their lacrimogenic property, 
were reacted with an in situ generated phenoxy and/or 
carboxylate ion. These condensation reactions were carried 
out in the presence of K2CO3 and butanone as solvent 
furnishing the products in yields ranging from 40 to 100%. 
The phenolic/carboxylic compounds were used in an excess 
of 2% instead of using excess of α-bromoketone. During 
isolation, the volume of solvent was reduced to 1/3 of the 
initial volume before work-up, since the slight solubility 
of the solvents in water hampers the isolation procedure.
In order to obtain compounds 7a-7b and 8, previous 
esterification of the cinnamic acid derivatives with 
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methanol and sulfuric acid was mandatory to avoid the 
competitive nucleophilic displacement of the bromine 
atom by the carboxylate anions. This was confirmed in 
the obtention of compounds 4a-4c and 5a-5b by using 
2 equivalents of 2a-2b. As far as we know, this creates a 
new subclass of 8,4’-oxyneolignan analogues, which we 
called 8,4’-oxyneolignan cinnamic analogues. Compound 9 
was synthesized in a similar fashion.
Scheme 1. Synthesis of 8,4’-oxyneolignan analogues. Reagents and conditions: (i) Br2, CHCl3 r.t. 2 h; (ii) ArOH, K2CO3, butanone or MeCN, 80 °C, 12 h; 
(iii) cinnamic acids, K2CO3, butanone or MeCN, 80 °C; (iv) methyl ferulate, butanone or MeCN, 80 °C, 12 h; (v) methyl 3-hydroxycinnamate, K2CO3, 
butanone or MeCN, 80 °C; (vi) 4-hydroxy-benzoic acid, K2CO3, butanone, 80 °C.
Synthesis, Characterization and in vitro Anticancer Activity of Novel 8,4’-Oxyneolignan Analogues J. Braz. Chem. Soc.2236
Table 1. Chemical structures, yields, and melting points (mp) of the synthesized compounds
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Table 1. Chemical structures, yields, and melting points (mp) of the synthesized compounds (cont.)
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Table 1. Chemical structures, yields, and melting points (mp) of the synthesized compounds (cont.)
The 1H NMR spectra of the products show the 
presence of one peak (compounds 3, 6, 7 and 8) or two 
peaks (compounds 4, 5 and 9) in between 5.12-6.14 ppm, 
assignable to the CH2/CH carbinolic protons. These 
signals confirm the formation of the C-O-C bond and, 
consequently, the expected products.
All synthesized substances were purified by 
crystallization and fully characterized by usual spectroscopic 
methods (melting points, HRMS, 1H and 13C NMR). The 
chemical structures are described in Table 1.
Biology
To evaluate the antiproliferative activity, the amount of 
surviving cells at the dose level of 10 μM was measured 
after 24 h of incubation by the MTT method colorimetric 
assay35 and the results were expressed as percentage 
of inhibition relative to control and compared with the 
reference drug (doxorubicin). The tests were carried out in 
triplicate, using doxorubicin as positive control and these 
data are schematically listed in Table 2.
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The antiproliferative screening results show that 
five compounds presented a promising antiproliferative 
activity (≥ 50% of cell inhibition) against the leukemia cell 
lines. The other analogues were less active or completely 
inactive at the dose of 10 μM. Compounds 4a, 4b, 6d and 
9 (entries 11, 12, 19 and 25, respectively) demonstrate 
similar inhibition of growth proliferation against HL-60, 
Ramos and Nalm-6 (48.6-66.7%). The same substances did 
not reveal a good inhibition level against K-562 cells. The 
best compound of the series was 6c (entry 18) inhibiting 
cell proliferation over 50% against four leukemia cell lines 
and very comparable to the positive control used in this test 
(entry 26). For Nalm-6 and Ramos cells, the percentage 
of inhibition was even superior to doxorubicin inhibition, 
presenting 73.2 and 84.6%, respectively.
Compounds which presented significant activity profile 
against leukemia cells (4a, 4b, 6c, 6d, 9) were selected 
to be evaluated for their activity on cell proliferation on 
other nineteen different kinds of human neoplasms, among 
tumors and leukemia cell lines. These tests were performed 
by using the MTT method, as previously mentioned. The 
cells used in this evaluation are listed in the Experimental 
section and the obtained results are shown on Tables 3-4 
and Figures 1-2.
As can be seen from Table 3 and Figures 1-2, all 
compounds exhibited some degree of activity against 
the eleven tumor cells used in this assay. β-Ketoester 6c 
presented a good antiproliferative activity for tumors, 
specially LNCaP (74.9%), HOS (68.3%) and MG-63 
(70.2%), whereas compound 6d showed an inhibition rate 
greater than 50% only for LNCaP (50.6%), HeLa (51.4%) 
and HOS (65.0%) tumors. The oxyneolignan analogue 9 
demonstrated a considerable reduction of cell growth on 
four tumor cells: LNCaP (50.0%), NCI/ADR (58.4%), 
U-138 MG (53.0%) and MG-63 (54.0%).
Table 2. Evaluation of cytotoxicity towards leukemia cells (% inhibition)a 
for all synthesized compounds
entry Compound K-562 HL-60 Nalm-6 Ramos
1 3a 11.8 15.4 < 5 14.7
2 3b 15.6 4.8 5.8 21.0
3 3c 20.4 10.9 8.7 < 5
4 3d 28.3 26.1 13.4 29.8
5 3e NT NT NT NT
6 3f 17.2 1.4 < 5 15.0
7 3g 34.4 6.5 < 5 18.6
8 3h 13.9 16.9 < 5 10.4
9 3i 10.3 8.7 14.1 18.5
10 3j 27.4 38.1 < 5 17.6
11 4a 34.1 52.1 56.7 48.6
12 4b < 10 57.5 62.0 60.4
13 4c NT NT NT NT
14 5a 21.6 < 5 12.4 17.9
15 5b 12.2 < 5 8.6 15.7
16 6a 39.3 34.1 32.6 43.7
17 6b 27.8 7.1 21.7 42.8
18 6c 52.2 86.3 73.2 84.6
19 6d < 5 51.4 56.9 61.3
20 6e 43.6 33.2 38.5 38.3
21 6f 19.9 33.7 34.9 36.9
22 7a NT NT NT NT
23 7b 13.7 16.3 < 5 9.9
24 8 12.8 14.8 9.9 21.7
25 9 47.0 66.7 51.6 54.1
26 doxorubicin 71.1 97.7 65.4 81.3
aInhibition percentages measured at a single concentration of 10 μM. 
NT: not tested.
Table 3. Evaluation of antiproliferative activity towards tumor cells 
(% inhibition at 10 μM) for compounds 4a, 4b, 6c, 6d and 9
Tumor
Antiproliferative activity / (% inhibition at 10 μM)
4a 4b 6c 6d 9 Doxorubicin
PC3 82.9 67.3 57.1 47.1 47.5 85.1
LNCaP 64.3 67.6 74.9 50.6 50.0 86.0
NCI/ADR 76.2 56.5 60.1 42.6 58.4 94.0
MCF-7 39.7 35.2 59.0 31.2 36.5 72.1
HeLa 61.3 71.1 36.3 51.4 33.7 93.7
U-87 72.2 34.2 43.4 32.1 50.0 59.0
U-138 MG 75.7 5.4 29.8 27.0 53.0 73.2
HOS 76.3 66.6 68.3 65.0 27.5 91.5
U-2 OS 21.2 52.0 41.9 35.2 20.9 90.5
MG-63 71.7 59.4 70.2 36.9 54.0 74.5
H1299 73.4 24.8 15.0 23.1 35.5 65.4
Table 4. Evaluation of cytotoxicity towards leukemia cells (% inhibition 
at 10 μM) for compounds 4a, 4b, 6c, 6d and 9
Leukemia 
cell
Cytotoxicity / (% inhibition at 10 μM)
4a 4b 6c 6d 9 Doxorubicin
KG-1 55.1 92.0 89.7 34.0 < 5 86.9
NB4 33.2 48.9 81.4 35.2 45.0 88.2
RAJI 19.6 37.9 65.5 46.3 37.1 90.8
JURKAT 56.8 62.2 91.2 51.9 40.8 97.5
CEM 52.4 61.7 91.1 45.6 57.8 98.4
MOLT-4 14.1 41.5 87.1 34.0 62.0 90.0
SUP-B15 48.5 57.4 64.4 51.7 56.4 89.4
RS4;11 53.0 40.5 89.6 35.8 50.5 95.2
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8,4’-Oxyneolignan cinnamic analogues 4a and 4b were 
shown to be active against most cells, exhibiting a good 
inhibition profile. The most active compound was 4a, 
showing a significant inhibition rate of cell growth against 
PC3 (82.9%), MG-63 (71.7%), U-87 (72.2%), U-138 MG 
(75.7%) and H1299 (73.4%) tumors. In these last three 
cell lines results, the activity of the oxyneolignan 4a was 
even superior to that of doxorubicin, the positive control 
used in this trial.
The evaluation of compounds 4a, 4b, 6c, 6d and 9 on 
leukemic cells are expressed in Table 4 and Figures 3-4.
Compound 9 was most active against CEM, SUP-B15, 
MOLT-4 and RS4;11 cells, reducing its growth by 50.5 to 
62.0%. Compound 4a presented levels of cell inhibition 
against KG-1, JUKART, CEM, RS4;11 around 52.4-56.8%, 
whereas a great selectivity and stronger antiproliferative 
activity were observed for compound 4b, which exhibited 
92.0% of inhibition against KG-1 cells.
Compound 6c was found to be the most promising of 
the series, presenting antileukemic activity higher than 
50% for all cell lines used in this study and superior or 
comparable results when compared to the reference drug. 
In the case of KG-1 cells, the extent of inhibition levels 
of products 4b and 6c were even better than doxorubicin, 
indicating its possible efficacy against this leukemia type.
Considering the results obtained in the antiproliferative 
tests (Table 4, Figure 4), in vitro cytotoxicity assay was used 
to assess the activity of the most potent compound (6c). 
The analogue was tested against eleven human leukemic 
cell lines. The assays were carried out in triplicate, and 
doxorubicin was used as the positive control. The biological 
endpoint was determined according to the concentration, 
Figure 1. MTT assay for human tumor cell lines of compounds 6c, 6d and 9.
Figure 2. MTT assay for human tumor cell lines of compounds 4a and 4b.
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which causes fifty percent of cell growth inhibition (IC50). 
Compound 6c showed similar values of IC50 against 
leukemia cells (Table 5), ranging from moderate to good 
activity, except for K-562 cells, for which the drug showed 
no activity. Compound 6c induced better cytotoxic effects 
on Ramos cells, which presented an IC50 of 9.4 μM.
The correlation between the structures of the synthesized 
compounds and their antiproliferative activities leads to the 
conclusion that the compounds bearing a cinnamic moiety 
on its structure possess better potency in MTT assay. The 
presence of the cinnamic portion in the basic structure of 
the 8,4’-oxyneolignans and the variation on its position on 
the aromatic ring affect considerably the antiproliferative 
activities. When comparing compounds 4a-4b and 5a-5b, 
7a-7b and 8 better inhibition showed by compounds 4a 
and 4b against cancer cells could be attributed to its para 
substitution, whereas meta-substituted compounds 5a-5b 
did not show an expressive percentage of inhibition. 
However, in compounds 7a-7b and 8, the cinnamate moiety 
and the absence of an aromatic ring may be responsible for 
the drastic decrease in activity.
In the 8,4’-oxyneolignans 3a-3j, the effects of 
substitution on the aromatic rings were not clearly 
observed. These compounds did not show enhanced activity 
when comparing substituent groups, positions and side 
chain length.
Among compounds 6a-6f, as shown in Tables 2 and 3, 
the effect of alkyl chain substitution in compound 6c greatly 
Figure 3. MTT assay for human leukemia cell lines of compounds 4a, 6d and 9.
Figure 4. MTT assay for human leukemia cell lines of compounds 4b and 6c.
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decreased cell proliferation when compared to compound 
6a. In the same aspect, the presence of a halogen substituent 
in compound 6d intensified the cytotoxicity level compared 
to 6a and also compared with 6b, which possesses an 
electron-withdrawing group at the same position. These 
results suggest that the electronic characteristics of the 
substituent groups and the alkyl chain affect the capability of 
the molecule to interact with the bioactive target increasing/
decreasing the antiproliferative activity.
Conclusions
From our study we were able to produce a new subclass 
of neolignan analogues, the 8,4’-oxyneolignan cinnamic 
analogues. These compounds were evaluated against a 
variety of cancer cell lines, among tumors and leukemias. 
In tumor cells assays we identified that compound 4a 
showed an antiproliferative activity superior to doxorubicin 
for U-87, U-138 MG and H1299 cell types. Compound 6c 
exhibited significant inhibition activity in a range of 52.2 
to 91.2% against twelve kinds of leukemia cell lines, 
revealing excellent results and very comparable to the 
reference drug. In addition, compound 4b was found 
to be very selective, demonstrating a growth inhibition 
of 92.0% against KG-1 cells. These preliminary results 
suggest that further investigation is needed to elucidate the 
characteristics underlying the antiproliferative activities of 
these analogues.
Supplementary Information
The supplementary data of 1H NMR, 13C NMR and 
HRMS spectra of all compounds synthesized are available 
free of charge at http://jbcs.org.br as a PDF file.
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